Dawn Health and Merck have launched a next-generation digital ecosystem focused on improving care for patients with Growth Hormone Deficiency (GHD). The ecosystem includes an enhanced mobile application and an upgraded portal for healthcare professionals (HCPs), both designed to streamline treatment management and improve patient outcomes. This digital health platform supports patients, caregivers, and clinicians by providing user-friendly tools that enhance engagement, data tracking, and communication.

Built on the Dawn Platform, the updated mobile app incorporates child-friendly elements to help young patients engage with their treatment, while offering caregivers a structured interface to monitor progress and stay informed. The HCP portal has been redesigned to allow clinicians to efficiently track patient growth and treatment adherence while gaining timely clinical insights. Features such as advanced security and localization enable the platform’s scalability and support a global rollout.

This release also lays the foundation for future enhancements, with planned integration of AI-powered features including real-time data capture, personalized treatment guidance, and predictive analytics. The collaboration between Dawn Health and Merck signals a shared commitment to advancing digital innovation in growth disorder management and setting a new standard for patient-centered, technology-driven healthcare solutions.

MedTech Spectrum's Summary

Dawn Health and Merck launched a next-gen digital ecosystem to enhance care for Growth Hormone Deficiency (GHD) patients, caregivers, and healthcare professionals.

The platform features a redesigned app and HCP portal, offering improved usability, child-friendly interfaces, treatment tracking, and clinical insights.

Future updates will introduce AI-driven capabilities, such as growth predictions and real-time data capture, aiming to set a new standard in digital health for growth disorders.